OncoMatch/Clinical Trials/NCT06983743
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Is NCT06983743 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including ERAS-0015 and ERAS-0015 in combination for metastatic solid tumors.
Treatment: ERAS-0015 · ERAS-0015 in combination — The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG PS of 0 or 1
Demographics
Prior therapy
Cannot have received: RAS inhibitor
Previous treatment with a RAS inhibitor
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Adequate cardiovascular, hematological, liver, and renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas at Tyler · Tyler, Texas
- NEXT Virginia · Fairfax, Virginia
- Florida Cancer Specalists · Sarasota, Florida
- Moffitt Cancer Center · Tampa, Florida
- Massachusetts General Hospital (MG) · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06983743 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior RAS inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify